Skip to main content
Top
Published in: Journal of Cardiovascular Translational Research 2/2020

01-04-2020 | Implantable Cardioverter Defibrillator | Original Article

Atrial Fibrillation Is Associated with Recurrent Ventricular Arrhythmias After LVAD Implant: Incidence and Impact in a Consecutive Series

Authors: Kathleen T. Hickey, Paolo C. Colombo, Yoshifumi Naka, Arthur R. Garan, Melana Yuzefpolskaya, Hasan Garan, Elaine Y. Wan, Robert R. Sciacca, Isaac Goldenthal, Angelo B. Biviano

Published in: Journal of Cardiovascular Translational Research | Issue 2/2020

Login to get access

Abstract

This study examined left-ventricular assist device (LVAD) patients with pre-LVAD ventricular arrhythmias (VAs) to determine the rate of recurrent post-LVAD VAs and the impact of pre-LVAD atrial fibrillation (AF) on recurrent post-LVAD VAs. Medical records of 195 consecutive LVAD patients were reviewed. Descriptive statistics were generated and Cox proportional hazard models were used to assess the association of clinical variables with the time to recurrent VA. Forty-seven percent of 195 CHF patients who received LVAD-manifested significant VAs prior to LVAD implant (82% Heartmate II, 14% HVAD, 4% other; median follow-up = 17 months), 41% of whom manifested recurrent post-LVAD VAs. Pre-LVAD AF was associated with recurrent VAs (hazard ratio = 3.73; 95% CI 1.33, 10.48; p = 0.012). Recurrent VAs were associated with increased mortality (hazard ratio = 3.06; 95% CI 1.17, 7.98; p = 0.023). A history of AF is prevalent in over half of LVAD patients with recurrent VAs and is associated with time to recurrence of VA.
Literature
1.
go back to reference Enriquez, A. D., et al. (2014). Clinical impact of atrial fibrillation in patients with the HeartMate II left ventricular assist device. Journal of the American College of Cardiology, 64(18), 1883–1890.CrossRef Enriquez, A. D., et al. (2014). Clinical impact of atrial fibrillation in patients with the HeartMate II left ventricular assist device. Journal of the American College of Cardiology, 64(18), 1883–1890.CrossRef
2.
go back to reference Brenyo, A., et al. (2012). Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. Journal of Cardiovascular Electrophysiology, 23(5), 515–520.CrossRef Brenyo, A., et al. (2012). Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. Journal of Cardiovascular Electrophysiology, 23(5), 515–520.CrossRef
3.
go back to reference Oswald, H., et al. (2010). Implantable defibrillator therapy for ventricular tachyarrhythmia in left ventricular assist device patients. European Journal of Heart Failure, 12(6), 593–599.CrossRef Oswald, H., et al. (2010). Implantable defibrillator therapy for ventricular tachyarrhythmia in left ventricular assist device patients. European Journal of Heart Failure, 12(6), 593–599.CrossRef
4.
go back to reference Andersen, M., et al. (2009). Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). The Journal of Heart and Lung Transplantation, 28(7), 733–735.CrossRef Andersen, M., et al. (2009). Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). The Journal of Heart and Lung Transplantation, 28(7), 733–735.CrossRef
5.
go back to reference Garan, A. R., et al. (2013). Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? Journal of the American College of Cardiology, 61(25), 2542–2550.CrossRef Garan, A. R., et al. (2013). Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? Journal of the American College of Cardiology, 61(25), 2542–2550.CrossRef
6.
go back to reference Hickey, K. T., et al. (2016). Atrial fibrillation in patients with left ventricular assist devices: Incidence, Predictors, and Clinical Outcomes. JACC: Clinical Electrophysiology, 2(7), 793–798.PubMed Hickey, K. T., et al. (2016). Atrial fibrillation in patients with left ventricular assist devices: Incidence, Predictors, and Clinical Outcomes. JACC: Clinical Electrophysiology, 2(7), 793–798.PubMed
7.
go back to reference Efimova, E., et al. (2017). Predictors of ventricular arrhythmia after left ventricular assist device implantation: a large single-center observational study. Heart Rhythm, 14(12), 1812–1819.CrossRef Efimova, E., et al. (2017). Predictors of ventricular arrhythmia after left ventricular assist device implantation: a large single-center observational study. Heart Rhythm, 14(12), 1812–1819.CrossRef
8.
go back to reference Refaat, M., et al. (2008). Ventricular arrhythmias after left ventricular assist device implantation. Pacing and Clinical Electrophysiology, 31(10), 1246–1252.CrossRef Refaat, M., et al. (2008). Ventricular arrhythmias after left ventricular assist device implantation. Pacing and Clinical Electrophysiology, 31(10), 1246–1252.CrossRef
9.
go back to reference Kadado, A. J., Akar, J. G., & Hummel, J. P. (2018). Arrhythmias after left ventricular assist device implantation: incidence and management. Trends in Cardiovascular Medicine, 28(1), 41–50.CrossRef Kadado, A. J., Akar, J. G., & Hummel, J. P. (2018). Arrhythmias after left ventricular assist device implantation: incidence and management. Trends in Cardiovascular Medicine, 28(1), 41–50.CrossRef
11.
go back to reference Hottigoudar, R. U., et al. (2013). Catheter ablation of atrial flutter in patients with left ventricular assist device improves symptoms of right heart failure. Congestive Heart Failure, 19(4), 165–171.CrossRef Hottigoudar, R. U., et al. (2013). Catheter ablation of atrial flutter in patients with left ventricular assist device improves symptoms of right heart failure. Congestive Heart Failure, 19(4), 165–171.CrossRef
12.
go back to reference Somberg, J. C., et al. (2004). Enhancement of myocardial vulnerability by atrial fibrillation. American Journal of Therapeutics, 11(1), 33–43.CrossRef Somberg, J. C., et al. (2004). Enhancement of myocardial vulnerability by atrial fibrillation. American Journal of Therapeutics, 11(1), 33–43.CrossRef
13.
go back to reference Kotecha, D., et al. (2017). Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology, 69(24), 2885–2896.CrossRef Kotecha, D., et al. (2017). Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology, 69(24), 2885–2896.CrossRef
14.
go back to reference Packer, D. L., et al. (2018). Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: study rationale and design. American Heart Journal, 199, 192–199.CrossRef Packer, D. L., et al. (2018). Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: study rationale and design. American Heart Journal, 199, 192–199.CrossRef
15.
go back to reference Bardy, G. H., et al. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine, 352(3), 225–237.CrossRef Bardy, G. H., et al. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine, 352(3), 225–237.CrossRef
16.
go back to reference Moss, A. J., et al. (2009). Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England Journal of Medicine, 361(14), 1329–1338.CrossRef Moss, A. J., et al. (2009). Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England Journal of Medicine, 361(14), 1329–1338.CrossRef
17.
go back to reference Moss, A. J., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346(12), 877–883.CrossRef Moss, A. J., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346(12), 877–883.CrossRef
18.
go back to reference Makki, N., et al. (2015). Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. The American Journal of Cardiology, 116(9), 1385–1390.CrossRef Makki, N., et al. (2015). Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. The American Journal of Cardiology, 116(9), 1385–1390.CrossRef
19.
go back to reference Kirklin, J. K., et al. (2017). Eighth annual INTERMACS report: special focus on framing the impact of adverse events. The Journal of Heart and Lung Transplantation, 36(10), 1080–1086.CrossRef Kirklin, J. K., et al. (2017). Eighth annual INTERMACS report: special focus on framing the impact of adverse events. The Journal of Heart and Lung Transplantation, 36(10), 1080–1086.CrossRef
20.
go back to reference Enriquez, A. D., et al. (2013). The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circulation. Arrhythmia and Electrophysiology, 6(4), 668–674.CrossRef Enriquez, A. D., et al. (2013). The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circulation. Arrhythmia and Electrophysiology, 6(4), 668–674.CrossRef
Metadata
Title
Atrial Fibrillation Is Associated with Recurrent Ventricular Arrhythmias After LVAD Implant: Incidence and Impact in a Consecutive Series
Authors
Kathleen T. Hickey
Paolo C. Colombo
Yoshifumi Naka
Arthur R. Garan
Melana Yuzefpolskaya
Hasan Garan
Elaine Y. Wan
Robert R. Sciacca
Isaac Goldenthal
Angelo B. Biviano
Publication date
01-04-2020
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 2/2020
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-019-09914-0

Other articles of this Issue 2/2020

Journal of Cardiovascular Translational Research 2/2020 Go to the issue